ReviewCurrent neurology and neuroscience reports2012
Cost-effectiveness of disease-modifying therapies in multiple sclerosis.
Review in Current neurology and neuroscience reports, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02939859 (Use of Cellular Stromal Vascular Fraction), which is not on this map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Use of Cellular Stromal Vascular Fraction (cSVF) for Select Multiple Sclerosis, Autoimmune, Inflammatory, and Neurologic Conditions: Clinical Interventional Study of Adverse Events and Clinical Outcomes Using Autologous Stem-Stromal Cells.
Who cites it
11 citing papers in PubMed, 21 citations in OpenAlex.
- The contribution of type-I IFN-mediated neuroinflammation to Parkinson's disease progression.Brain, behavior, & immunity - health · 2025Review
- STING-Triggered CNS Inflammation in Human Neurodegenerative Diseases.Biomedicines · 2023Article
- Friend, Foe or Both? Immune Activity in Alzheimer's Disease.Frontiers in aging neuroscience · 2019Review
- Type-I interferon pathway in neuroinflammation and neurodegeneration: focus on Alzheimer's disease.Journal of neural transmission (Vienna, Austria : 1996) · 2018Review
- Article
- Carbon nanospheres mediated delivery of nuclear matrix protein SMAR1 to direct experimental autoimmune encephalomyelitis in mice.International journal of nanomedicine · 2016Article
- Cost-Effectiveness Modeling in Multiple Sclerosis: Playing Around with Non-Healthcare Costs?PharmacoEconomics · 2015Review
- The association of diet with quality of life, disability, and relapse rate in an international sample of people with multiple sclerosis.Nutritional neuroscience · 2015Article
- Social participation in patients with multiple sclerosis: correlations between disability and economic burden.BMC neurology · 2014Article
- Multiple sclerosis: basic knowledge and new insights in perioperative management.Journal of anesthesia · 2014Review
- Tobacco smoking and disability progression in multiple sclerosis: United Kingdom cohort study.Brain : a journal of neurology · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multiple sclerosis (MS) is a leading cause of disability among young adults and has a significant economic impact on society. Although MS is not currently a curable disease, costly treatments known as disease-modifying therapies (DMTs) are available to reduce the disease impact in certain types of MS. In the current economic downturn, cost-effectiveness analysis (CEA) of therapies in MS has become an important part of the decision-making process in order to use resources efficiently in the face of the rapidly escalating costs of MS. While some studies have reported costs of DMTs at the level of cost-effectiveness thresholds, some have estimated their costs beyond the tolerance level of health care systems. On the basis of the current literature and given the difficulties in accurately assessing cost-effectiveness in diseases like MS, it is challenging to determine whether DMTs are cost-effective. Further population-based studies are required regarding the cost-effectiveness of therapies in MS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.